RISK OF MALIGNANCY AND SEVERE INFECTION IN A POPULATION OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGICS OR DMARDS

被引：0
|
作者：
Gilliaux, Q. [1 ]
Stoenoiu, M. [1 ]
de Bellefon, L. Meric [1 ]
Depresseux, G. [1 ]
Toukap, A. Nzeusseu [1 ]
Lauwerys, B. [1 ]
Houssiau, F. [1 ]
Durez, P. [1 ]
机构：
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Clin Univ St Luc, Rheumatol,Serv & Pole Rhumatol, Brussels, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.6217
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0163
引用
收藏
页码：711 / 712
页数：2
相关论文
共 50 条
  • [1] Severe infection risk in patients treated with biologics for rheumatoid arthritis: a systematic review protocol
    Makimoto, Kiyoko
    Konno, Rie
    Kanzaki, Hatsumi
    Kinoshita, Atsushi
    JBI EVIDENCE SYNTHESIS, 2021, 19 (08) : 1992 - 1998
  • [2] CARDIOVASCULAR RISK ESTIMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS OR C-DMARDS
    Mole, Evangelia
    Gazi, Sousana
    Moschou, Dimitra
    Mpaili, Georgia
    Theodorakopoulos, Stavros
    Zoupidou, Konstantina
    Kontodimopoulos, Nikolaos
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1620 - 1620
  • [3] The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
    Soo-Kyung Cho
    Jiyoung Lee
    Minkyung Han
    Sang-Cheol Bae
    Yoon-Kyoung Sung
    Arthritis Research & Therapy, 19
  • [4] The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
    Cho, Soo-Kyung
    Lee, Jiyoung
    Han, Minkyung
    Bae, Sang-Cheol
    Sung, Yoon-Kyoung
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [5] Risk of Severe Infection among Rheumatoid Arthritis Patients on Biological DMARDs: A Population-Based Cohort Study
    Bellan, Mattia
    Scotti, Lorenza
    Ferrante, Daniela
    Calzaducca, Elisa
    Manfredi, Giulia Francesca
    Sainaghi, Pier Paolo
    Barone-Adesi, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
  • [6] ARE THE RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGICS WITH OR WITHOUT SYNTHETIC DMARDS IN CLINICAL PRACTICE DIFFERENT?
    Hernandez Cruz, B.
    Ariza Ariza, R.
    Caliz Caliz, R.
    Marquez Saavedra, E.
    Navarro Sarabia, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 407 - 407
  • [7] Denosumab, Biologics and the Risk of Infection in Patients with Rheumatoid Arthritis
    Haraoui, Boulos
    Choquette, Denis
    Coupal, Louis
    Sauvageau, Diane
    Zo'o, Alexandre Adjo'o
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1274 - 1274
  • [8] Risk of Serious Infection and Malignancy in Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Biologics
    Thyagarajan, Veena
    Norman, Heather
    Enger, Cheryl
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 160 - 160
  • [9] Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
    Jani, Meghna
    Barton, Anne
    Hyrich, Kimme
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 285 - 292
  • [10] Rheumatoid arthritis: Perioperative management of biologics and DMARDs
    Goodman, Susan M.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 44 (06) : 627 - 632
12345